Vobramitamab duocarmazine

DB18871InvestigationalProtein Based Therapies

Vobramitamab duocarmazine is under investigation in clinical trial NCT05551117 (A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors).

Mechanism: Pharmacologically active on CD276 antigen
Curator reviewed
Also known as: Anti-b7h3 antibody-drug conjugate mgc018
Code names: MGC-018

Resolves to

Compound

UNII2ZK3D69DQJCAS2490556-51-7

Targets

Q5ZPR3CD276

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vobramitamab duocarmazine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account